1. Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases.
- Author
-
Kobayashi I, Mori M, Yamaguchi K, Ito S, Iwata N, Masunaga K, Shimojo N, Ariga T, Okada K, and Takei S
- Subjects
- Child, Humans, Japan, Vaccines, Attenuated, Immunocompromised Host, Pediatrics, Rheumatic Diseases, Rheumatology, Vaccination
- Abstract
Pediatric Rheumatology Association of Japan has developed evidence-based guideline of vaccination in pediatric rheumatic diseases (PRDs) as a part of Guideline of Vaccination for Pediatric Immunocompromised Hosts. Available articles on vaccination in both adult rheumatic diseases and PRDs were analyzed. Non-live vaccines are generally safe and effective in patients with PRDs on corticosteroid, immunosuppressant, and/or biologics, although efficacy may be attenuated under high dose of the drugs. On the other hand, efficacy and safety of live-attenuated vaccine for the patients on such medication have not been established. Thus, live-attenuated vaccines should be withheld and, if indicated, may be considered as a clinical trial under the approval by Institutional Review Board. All patients with PRDs anticipating treatment with immunosuppressants or biologics should be screened for infection of hepatitis B and C and tuberculosis before the commencement of medication. Varicella vaccine should be considered in sensitive patients ideally 3 weeks or longer before the commencement of immunosuppressants, corticosteroids, or biologics. Bacille Calmette-Guérin should be withheld at least for 6 months after birth, if their mothers have received anti-tumor necrosis factor-α antibodies during the second or third trimester of pregnancy.
- Published
- 2015
- Full Text
- View/download PDF